# HSEF v5.3 review: Hygiene Hypothesis

> Sources: 63 primary reports; claims: 67; verified: 67; unverified: 0. Verification is bounded attribution. Access: 6 partial-body and 57 bounded abstract/status examinations. Literature cutoff: 2026-10-09; source examination UTC date: 2026-10-12. No complete-paper audit or blinded calibration claimed.
> **Adversarial review:** Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-14. 4 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: **Approved as revised.**

## AT A GLANCE

**Specific microbial exposures can shape immune regulation and prevent some eczema; a generalized hygiene-to-allergy-and-autoimmunity causal chain is not established.**

| Level | Confidence | Causal role | Momentum | Stability | Divergence |
|---|---|---|---|---|---|
| Γ — Mechanistically plausible, partial system support | Moderate | reinforcing / stabilizing factor | Mechanistic only | Stable | Contested |

**Deciding experiment:** Register microbial-factor/consortium restoration in an objectively baseline-defined infant population, with credible placebo, measured exposure/engagement and immune mediation. Prespecify clinical eczema, asthma and separately powered autoimmune endpoints, retain all randomized participants, and independently replicate dose/window and host-genotype predictions. Include antigen/diet/barrier and infection-indication controls.

**Belief versus evidence:** Overall Γ follows the registered complete human incidence SC3, with SC1 at Β and exposure-specific immune/clinical SC2 at Ε. Positive eczema trials and mechanistic recipient experiments are retained without claiming generalized protection from asthma or autoimmunity. Neither a universal biomarker cap nor a negative-trial veto is imposed on the narrow clinical successes; the broad conjunction has not crossed its own causal boundary.

**Best-supported rival:** Exposure-specific immune education. The randomized HN001/HN019 comparison (PMID18762327), defined-consortium/Treg necessity (PMID31235962), and the opposite-direction microbial peptidoglycan perturbation (PMID30833732) distinguish exposure-specific effects from a simple protective-quantity claim. ORBEX (PMID42705251) tests a prespecified human respiratory-prevention boundary, while LEAP (PMID25705822) supplies an orthogonal antigen-tolerance explanation.

## COMPETING MECHANISTIC MODELS

**Rank 1: Exposure-specific immune education (Ε).** Microbial factor, host pathway, dose and developmental window determine beneficial or harmful immune effects. Strain comparisons, Treg/epithelial necessity, timed colonization and clinical eczema effects define restricted causality. Does not yet predict every human allergic/autoimmune outcome or a universal optimal microbiome.

**Rank 2: Barrier and antigen-specific tolerance (Ε).** Food antigen timing and barrier/immune pathways can change selected allergy outcomes independently of microbial restoration. LEAP demonstrates food-specific clinical prevention; epithelial mechanisms supply a distinct causal route. Food exposure does not explain every farm association or prove systemic autoimmune protection.

**Rank 3: General microbial deprivation (Γ).** Reduced early microbial contact broadly causes allergic and autoimmune disease. Farm associations, recipient rescues and some positive prevention trials supply its strongest case. Clinical nulls, harmful microbial pathways, weak human autoimmune mediation and exposure heterogeneity prevent the registered generalization.

**Rank 4: Shared environment and indication effects (Γ).** Diet, barrier damage, genetics and infection/antibiotic indications generate part of the exposure-disease association. Familial/sibling constraints and different disease directions show alternatives that must be tested. Cannot erase randomized eczema effects or selective model pathway necessity.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

## FULL REVIEW

### Registered claim and scope

Reduced early-life microbial exposure causally increases the incidence of allergic and autoimmune disease.

SC3 is the causal claim at the registered human/disease or endogenous scope; narrower physiology, model interventions and associations are reported separately. Primary-subclaim aggregation is fixed before new grading.

Selection: remaining-priority list position 12 from the editorial list of 2026-10-09. Registered claim assessed against original sources. Any carried-forward edition and prior visibility are recorded in the change record; no independent blinded calibration is claimed.

### Evidence and causal interpretation

Rubric fit: 05 governs immune clinical causality; 04 governs consortium/strain evidence and recipient-to-human inference. Eczema is kept separate from sensitization, wheeze, diagnosed asthma, autoantibodies and clinical autoimmune disease. A narrow microbial-product prevention effect is not relabeled as population-wide loss-of-diversity mediation. The partial full-claim Γ is a scope/boundary adjudication, not an assertion that all included trials are biomarker-only.

Farm and sibling data are informative but endpoint-specific. Amish children were studied at school age and the dust experiment used adult mice; it establishes innate immune modulation in the model, not a randomized neonatal human exposure. European farm diversity and newer bacterial/metabolite mapping retain environmental and mediation assumptions. PMID27518660; PMID21345099; PMID42517701.

Clinical eczema effects deserve recognition: Finnish LGG and HN001 regimens have positive primary effects in defined settings. HN019, prenatal-only LGG, PROMPT, and other LGG studies are null for important endpoints; L. acidophilus can increase sensitization. Eczema is not identical to IgE sensitization or asthma. PMID11297958; PMID18762327; PMID21121927; PMID24247661; PMID28784701; PMID17208600.

Endpoint hierarchy changes the inference. The registered Wales trial is null for primary eczema despite selected secondary benefit; its electronic follow-up is the same parent study. The 13-year Finnish mixture report is null overall for allergy and presents a post-hoc cesarean result. ORBEX randomized 822 children aged 6–18 months to OM-85 or placebo for 24 months; its primary time-to-first wheezing LRT illness during the subsequent 36-month off-drug period is null (HR 1.16, CI 0.82–1.64). This result is clinical, not merely a lysate biomarker study. PMID24947281; PMID29769554; PMID30472801; PMID42705251.

Mechanisms are specific rather than interchangeable. Neonatal colonization changes iNKT-mediated susceptibility; defined consortia require Treg MyD88/RORgamma-t, but the tested SCFA mixture is ineffective and durable Clostridial detection is not established. LPS structural activity differs, and the NOD test uses intraperitoneal LPS. Neutralizing some endogenous microbial signals improves autoimmunity, while a commensal probiotic can worsen EAE in selected genotypes. PMID22442383; PMID31235962; PMID27133167; PMID30833732; PMID33077601.

Human autoimmunity data include both directions: early infection can precede islet autoimmunity, with timing-dependent protective and adverse associations in TEDDY. Diversity loss after seroconversion does not prove that deprivation initiated T1D. Antibiotic sibling comparisons reduce some familial confounding without eliminating indication or direct drug effects. PMID28597957; PMID37607456; PMID31744911; PMID25662751; PMID32132008.

Consensus usefully identified small blinded environmental interventions, but they measure short-term community/cytokine changes rather than clinical disease prevention. Its framing of consistently positive eczema trials and biomarker-only lysates is too broad given the original nulls and ORBEX. LEAP is compelling food-antigen tolerance evidence, not microbial restoration; EAT retains an overall intention-to-treat null. PMID35930838; PMID38688234; PMID25705822; PMID26943128.

## HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

### Subclaim matrix and aggregation

| Subclaim | Scope | Level | Decision |
|---|---|---|---|
| SC1 Early microbial exposure patterns predict later allergic or autoimmune disease. | Age, exposure setting, medication, disease and assay defined before outcome | Β | Farm, sibling, infant microbiome and antibiotic data repeatedly predict selected immune outcomes, but signs vary by disease, age and exposure. Familial, dietary, infection and indication effects are not uniformly eliminated. The registered predictive association component is Β, not a negation of specific causal interventions reported separately. |
| SC2 Defined microbial exposures causally alter immune regulation and disease susceptibility. | Defined strain, microbial factor, developmental window and model | Ε | Defined colonization, epithelial A20 and Treg MyD88/RORgamma-t controls establish context-specific immune/disease effects in recipient models. Selected randomized human microbial regimens also modify eczema risk, while others are null or adverse. This supports Ε for specified exposure/host/phenotype contexts, not an interchangeable class of protective microbes. |
| SC3 Reduced early-life microbial exposure causally increases human allergic and autoimmune disease incidence. | Human disease classes and measured early exposure; no post hoc protected subgroup | Γ | The complete human allergic-and-autoimmune incidence claim has partial mechanistic support, but no source set isolates a generalized early microbial deficit as the cause across the registered disease classes. Specific eczema prevention is real and retained; overall-null respiratory trials, bidirectional infection associations and harmful commensal mechanisms constrain transfer. Food-antigen tolerance and short-term soil immune markers cannot fill the missing autoimmune clinical branch. |

Preregistered aggregation: primary-subclaim. Overall Γ follows the registered complete human incidence SC3, with SC1 at Β and exposure-specific immune/clinical SC2 at Ε. Positive eczema trials and mechanistic recipient experiments are retained without claiming generalized protection from asthma or autoimmunity. Neither a universal biomarker cap nor a negative-trial veto is imposed on the narrow clinical successes; the broad conjunction has not crossed its own causal boundary. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

### Decisive-perturbation inventory and causal tally

[3] Perinatal LGG reduces primary eczema incidence in a high-risk randomized trial. Specific strain/regimen/phenotype; no proof of general asthma or autoimmune prevention.

[5] HN001 reduces eczema, while HN019 and sensitization comparisons are null. Strain and endpoint boundaries; probiotic exposure is not interchangeable with environmental diversity.

[9] Early L. acidophilus increases colonization without eczema prevention and with increased sensitization. Specific regimen; does not prove all microbial exposure harmful, but contradicts blanket benefit.

[11] Registered multispecies trial is null for primary diagnosed eczema, with selected positive secondary sensitization/atopic-eczema findings. Original Methods preserve broad recruited risk mix and endpoint hierarchy; secondary benefit is not primary success.

[19] ORBEX randomizes 822 children; OM-85 does not improve primary time to first wheezing lower-respiratory illness in the off-drug observation period. Wheezing endpoint and age/lysate regimen are defined; clinical null does not rule out every exposure, and target engagement was not verified here.

[43] Neonatal but not adult colonization prevents excess iNKT and induced lung/colitis pathology. Germ-free developmental deprivation and induced models require separate human adjudication.

[48] Defined live consortia suppress model food allergy through Treg MyD88/RORgamma-t necessity. SCFA mixture fails and durable Clostridial engraftment is not established; genetic allergy model and correction limit broad human transfer.

[55] Neutralizing circulating microbial peptidoglycan reduces autoimmune arthritis/EAE with NOD2 dependence. Adult systemic microbial-factor effects are not early-life deprivation, but show harmful commensal signaling can be causal.

Tally: 6 positive qualifying study units across scoped subclaims; 36 screened discriminating contrast units. These are not independent causal lines or proof of full-claim necessity/sufficiency. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Reports sharing participants, models or instruments are not independent causal lines. Pivotal nulls do not earn positive threshold crossings.

### Cap audit, precedence and Β/Γ/Δ boundary

Recipient colonization and immune-pathway perturbations cross within SC2's specified model context. The 04 transfer threshold and universal cap 5 bind different inferences: recipient causality is not endogenous human population causality. Clinical eczema trials are phenotypic interventions, so their restricted effect is not re-capped as a biomarker. Soil and immune-profile studies remain cap-4 limited for disease prevention. Clinical and model directions vary without deleting unsuccessful subjects or strains from scope.

Universal six-cap audit: All six universal caps were considered: cell-only inference, unperturbed association, ectopic expression, biomarker-only intervention, forced transfer/seeding, and inherited-to-sporadic scope transfer. Each binds its offered inference; complementary same-scope causal classes are assessed together rather than re-capped in isolation.

Gamma hard-rule audit: Positive restricted experiments retain their experimental scope; associations and proxy movement do not establish the complete clinical claim.

SC1 cap: “Pure association evidence — however large, however replicated — cannot exceed Β.” Farm, sibling, infant microbiome and antibiotic data repeatedly predict selected immune outcomes, but signs vary by disease, age and exposure. Familial, dietary, infection and indication effects are not uniformly eliminated. The registered predictive association component is Β, not a negation of specific causal interventions reported separately.

SC1 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. Farm, sibling, infant microbiome and antibiotic data repeatedly predict selected immune outcomes, but signs vary by disease, age and exposure. Familial, dietary, infection and indication effects are not uniformly eliminated. The registered predictive association component is Β, not a negation of specific causal interventions reported separately.

SC2 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: yes. Defined colonization, epithelial A20 and Treg MyD88/RORgamma-t controls establish context-specific immune/disease effects in recipient models. Selected randomized human microbial regimens also modify eczema risk, while others are null or adverse. This supports Ε for specified exposure/host/phenotype contexts, not an interchangeable class of protective microbes.

SC3 field-valid definition: “
- Cell-type-specific conditional knockout or depletion
- Pathway-specific blockade (not broad immunosuppression) changing disease course
- Human targeted therapy with mechanistic alignment showing disease-modifying effect” Positive full-scope result: no. The complete human allergic-and-autoimmune incidence claim has partial mechanistic support, but no source set isolates a generalized early microbial deficit as the cause across the registered disease classes. Specific eczema prevention is real and retained; overall-null respiratory trials, bidirectional infection associations and harmful commensal mechanisms constrain transfer. Food-antigen tolerance and short-term soil immune markers cannot fill the missing autoimmune clinical branch.

### Upward threshold ladder

SC1 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. A causal claim above association needs prospective microbial identity/quantity measurement with stronger genetic/familial and indication controls or a selective exposure instrument against the prespecified disease endpoint.

SC2 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: yes. 

SC2 Ε: “Requires context-specific causality with explicit scope restriction.” Satisfied: yes. 

SC2 Ζ: “Requires multiple convergent causal manipulations and reduced plausibility of downstream-only interpretations.” Satisfied: no. Independent exposure/strain and host-pathway manipulations with rescue must replicate clinical or functional effects across relevant contexts and constrain developmental, cage, diet and delivery confounds.

SC3 Δ: “Requires pathway- or cell-type-resolved causal perturbation affecting disease or phenotype.” Satisfied: no. Prospectively register defined microbial restoration versus credible control in baseline-defined human settings, verify engagement, and measure clinical allergic and autoimmune incidence over sufficient follow-up. Replicate beyond one strain/regimen and do not select protected subgroups after results.

Upper ladder: Defined consortium rescue, selective host-cell mediator loss, human prevention randomization and farm/genetic/sibling comparisons were considered. They constrain distinct errors in narrow contexts. No broad same-scope causal set is re-capped from one weak observational leg, but the examined human autoimmune and generalized deprivation branches remain incomplete. The upper ladder remains reachable with an appropriate clinical intervention or natural experiment.

Independence: Finnish LGG follow-ups/subsets, Finnish probiotic-mixture reports, HN001/HN019 follow-ups and genotype analyses each share parent randomization. PASTURE and related farm cohorts share recruitment and environmental measurements. TEDDY and DIABIMMUNE reports can overlap participants. One trial reported several times counts as one causal line; different clinical products are not interchangeable mechanism replications.

Specific human prevention randomizations [3, 5, 11, 19]: Constrain baseline confounding, with product, outcome and timing differences rather than one shared protective effect.

Defined microbial and cellular mechanism [47, 48, 43]: Constrain a purely associational explanation in models; induction, recipient physiology and developmental conditions remain.

Farm and prospective population patterns [1, 2, 27, 28]: Constrain trial-product-only interpretation, but correlated environments and reused cohort resources remain.

Contrary autoimmune directions [55, 57, 51, 52]: Constrain blanket microbial benefit, with host genotype, infection identity and biomarker-to-clinical endpoint limits.

### Falsification and pitfalls

Generalization fails across interventions, endpoints and host contexts. Clinical nulls, increased sensitization and harmful microbial signaling oppose blanket protection; narrow causal effects remain. Additional downgrade: False.

Quantity replaces exposure identity. Commensals, pathogens, microbial metabolites, diversity and dose can produce different directions.

Secondary/subgroup outcomes promoted. Overall trial nulls and post-hoc cesarean benefit remain distinct.

Antigen tolerance credited to microbes. LEAP/EAT manipulate food introduction, not microbial exposure.

Recipient-to-human transfer. Germ-free and induced-allergy models retain their own causal scope.

### Adversarial steelman: above, then below

One rung above, Δ: randomized microbial regimens prevent some clinical eczema and model rescues identify immune mechanisms. Yet the registered SC3 includes generalized human allergic and autoimmune incidence from reduced exposure, not only a supplied product's eczema effect. Human autoimmune clinical mediation and transferable prospective context prediction remain unverified.

One rung below, Β: population farm/diversity data are associational and recent clinical respiratory-prevention data are null. However, selective consortia/pathway experiments and genuine clinical eczema randomizations supply mechanistic and restricted causal content beyond association.

Retain Γ for the broad SC3 with narrow SC2 Ε. Reject both generalized clinical protection and a claim that microbes have no causal immune effects.

### Final score, causal direction and M/S/D

Overall Γ follows the registered complete human incidence SC3, with SC1 at Β and exposure-specific immune/clinical SC2 at Ε. Positive eczema trials and mechanistic recipient experiments are retained without claiming generalized protection from asthma or autoimmunity. Neither a universal biomarker cap nor a negative-trial veto is imposed on the narrow clinical successes; the broad conjunction has not crossed its own causal boundary.

Selective model perturbations and clinical eczema effects show that microbial exposure is not merely an outcome marker in all settings. Both harmful and protective immune effects occur. Universal prevention, initiation and rate limitation for the registered disease classes are not demonstrated, nor universal requirement. Step 5 supports a context-dependent immune susceptibility modifier; its direction must be specified by factor and host.

Momentum: Mechanistic only. Defined Treg MyD88/RORgamma-t manipulations (PMID31235962), recent farm-factor mapping (PMID42517701) and blinded environmental biodiversity interventions (PMID35930838, PMID38688234) test immune mechanisms. ORBEX supplies completed clinical boundary evidence; no new outcome is assumed for protocol-only programs.

Stability: Stable. No verified named pending result was identified that demonstrably determines the full-scope letter; this is a bounded search finding, not proof that none exists.

Divergence: Contested. Required artifact: the two framings carry different implied levels, so no single implied level and no arithmetic gap can be stated. Popular and much review-level framing treats loss of early microbial exposure as an established cause of the rise in allergy and autoimmunity, which would imply a level well above the assessed Γ for the registered conjunction, while the trial literature cited here is a mixture of a few positive eczema results and overall-null respiratory and autoimmune branches. No manufactured field consensus is asserted. These dimensions do not change level or confidence.

## PROPOSED DECISIVE EXPERIMENTS

Register microbial-factor/consortium restoration in an objectively baseline-defined infant population, with credible placebo, measured exposure/engagement and immune mediation. Prespecify clinical eczema, asthma and separately powered autoimmune endpoints, retain all randomized participants, and independently replicate dose/window and host-genotype predictions. Include antigen/diet/barrier and infection-indication controls.

Readout: Prespecified clinical disease incidence and mediator engagement over sufficient pediatric follow-up. Controls: Product identity/viability, dose, colonization versus transient exposure, maternal/infant timing, diet and allergens, barrier status, antibiotic indication, pathogen infection and familial risk. Supporting: Defined restoration changes clinical incidence with the predicted immune mediator and independently replicated baseline context. Falsifying: Adequate engagement changes only immune markers, fails clinical endpoints, or harms predefined groups; apparent benefit is confined to unregistered subgroup analyses.

## KNOWLEDGE GAPS

Microbial quality, amount, route and timing are distinct exposures, not one hygiene variable.

Human autoimmune clinical prevention remains a separate missing causal branch.

Positive eczema effects do not consistently extend to sensitization, food allergy or asthma.

Clinical effects may occur without durable microbial engraftment or diversity change; the mediator needs identification.

Environmental soil interventions need disease-incidence follow-up beyond immune biomarkers.

Shared cohort/trial reports and post-hoc genotype/delivery subgroups require prospective independent validation.

## REVIEWER NOTES

Original primary abstracts/status records and selected body passages were examined. Most full papers and supplements were not audited. Consensus browser synthesis supplements discovery and original-source reconciliation. No independent blinded grading or scientific peer review is claimed.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

## Consensus and original-source reconciliation

The original Finnish trial supports reduced eczema in a specified high-risk perinatal LGG regimen. This restricted positive result does not establish a universal probiotic effect, prevent every allergy, or identify protection from autoimmune disease. [Original PMID11297958](https://pubmed.ncbi.nlm.nih.gov/11297958/).

In the original randomized comparison HN001 reduced eczema while HN019 did not, and atopy comparisons were nonsignificant. Consensus's broad wording about consistently positive eczema trials must retain this strain-specific contrast. [Original PMID18762327](https://pubmed.ncbi.nlm.nih.gov/18762327/).

The original Wales trial had a null primary diagnosed-eczema comparison, with favorable secondary sensitization and atopic-eczema results. The body also shows enrollment of both familial-risk levels. The later five-year follow-up is the same parent trial, not independent replication. [Original PMID24947281](https://pubmed.ncbi.nlm.nih.gov/24947281/).

Consensus omitted ORBEX and portrayed bacterial-lysate evidence as largely biomarker-based. The original 822-participant report tested a clinical primary endpoint during subsequent off-treatment observation and found no significant benefit: hazard ratio 1.16, confidence interval 0.82–1.64. It is a completed clinical null, not an unreported biomarker-only study. [Original PMID42705251](https://pubmed.ncbi.nlm.nih.gov/42705251/).

The original small randomized soil-enrichment study reports microbiome and immune-marker changes over 14 days. It does not demonstrate prevention of diagnosed allergy or autoimmunity. Consensus helped locate this original source, but the marker-to-disease boundary remains. [Original PMID35930838](https://pubmed.ncbi.nlm.nih.gov/35930838/).

The original report pairs observational infant cohorts with injected LPS experiments in NOD mice. E. coli and B. dorei signals differ. It supports exposure-specific biology rather than a general rule that more microbes protect humans; the linked correction is retained, with its detailed changes unexamined. [Original PMID27133167](https://pubmed.ncbi.nlm.nih.gov/27133167/).

Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.

## Research timeline and gaps: Hygiene Hypothesis

Selected publication milestones, not an exhaustive history or discovery priority claim.

**2001 — A defined perinatal probiotic regimen tests eczema prevention.** [Original PMID11297958](https://pubmed.ncbi.nlm.nih.gov/11297958/).

**2008 — Microbiota and host genotype interact in experimental autoimmune diabetes.** [Original PMID18806780](https://pubmed.ncbi.nlm.nih.gov/18806780/).

**2012 — Neonatal versus adult colonization distinguishes an immune-development window in mice.** [Original PMID22442383](https://pubmed.ncbi.nlm.nih.gov/22442383/).

**2015 — Early microbial taxa link human risk observations with recipient-mouse airway experiments.** [Original PMID26424567](https://pubmed.ncbi.nlm.nih.gov/26424567/).

**2016 — Amish–Hutterite observations combine with contrasting dust perturbations in mice.** [Original PMID27518660](https://pubmed.ncbi.nlm.nih.gov/27518660/).

**2016 — Different bacterial LPS signals link human cohorts with NOD-mouse experiments.** [Original PMID27133167](https://pubmed.ncbi.nlm.nih.gov/27133167/).

**2022 — Daycare biodiversity intervention tests immune and microbiome markers.** [Original PMID35930838](https://pubmed.ncbi.nlm.nih.gov/35930838/).

**2026 — ORBEX reports a null clinical primary outcome after bacterial-lysate treatment.** [Original PMID42705251](https://pubmed.ncbi.nlm.nih.gov/42705251/).

## Research gaps

Microbial quality, amount, route and timing are distinct exposures, not one hygiene variable.

Human autoimmune clinical prevention remains a separate missing causal branch.

Positive eczema effects do not consistently extend to sensitization, food allergy or asthma.

Clinical effects may occur without durable microbial engraftment or diversity change; the mediator needs identification.

Environmental soil interventions need disease-incidence follow-up beyond immune biomarkers.

Shared cohort/trial reports and post-hoc genotype/delivery subgroups require prospective independent validation.

## Boundary experiment

Register microbial-factor/consortium restoration in an objectively baseline-defined infant population, with credible placebo, measured exposure/engagement and immune mediation. Prespecify clinical eczema, asthma and separately powered autoimmune endpoints, retain all randomized participants, and independently replicate dose/window and host-genotype predictions. Include antigen/diet/barrier and infection-indication controls.


## ADVERSARIAL REVIEW AND APPROVAL

**Authoring model:** Sol 6.1. **Adversarial reviewer:** Claude Opus 5.5 (Anthropic). **Date:** 2026-10-14.

**Scope of checks.** All 63 REFERENCES PMIDs were verified against PubMed metadata for title, first author, journal, year and DOI: 63/63 resolve to the stated record, 0 failures, no retraction or expression-of-concern flag. Twelve load-bearing claims were spot-checked against the primary abstracts: the ORBEX design and result, where 822 children aged 6 to 18 months received OM-85 or placebo for 24 months and the primary time to first wheezing lower respiratory tract illness over the subsequent 36 off-drug months gave a hazard ratio of 1.16 with a 95% confidence interval of 0.82 to 1.64 and a log-rank p of 0.35 (PMID 42705251); the differential probiotic trial in which L rhamnosus HN001 reduced eczema with a hazard ratio of 0.51 while B lactis HN019 did not, and neither changed atopy (PMID 18762327); the Welsh multistrain trial, null for its primary diagnosed-eczema endpoint at an odds ratio of 1.07 with a positive secondary sensitisation finding (PMID 24947281); its five-year electronic follow-up of the same cohort, which found no protection against asthma or eczema (PMID 29769554); the original Finnish perinatal LGG trial, in which eczema frequency was halved at a relative risk of 0.51 (PMID 11297958); the L acidophilus trial, which failed to prevent atopic dermatitis and significantly increased sensitisation (PMID 17208600); the Amish and Hutterite comparison, with asthma and sensitisation four and six times lower in the Amish, 6.8 times higher house-dust endotoxin, and dust extracts tested in a murine asthma model (PMID 27518660); the food-allergy bacteriotherapy result, where protection required ROR-gamma-t induction in regulatory T cells through MyD88 and was abolished by deleting Myd88 or Rorc in those cells (PMID 31235962); the neonatal-but-not-adult colonization window for invariant natural killer T cells (PMID 22442383); the antibody neutralization of circulating microbiota-derived peptidoglycan, which suppressed autoimmune arthritis and experimental autoimmune encephalomyelitis through NOD2 (PMID 30833732); the host-genotype-by-microbiome determination of central nervous system autoimmunity across 29 genotypes (PMID 33077601); and the Finnish, Estonian and Russian Karelian cohort in which early childhood infections preceded islet autoimmunity (PMID 28597957). All twelve matched the review. Scoring logic was re-derived independently of the recorded letter: universal cap 2 on SC1, the preregistered primary-subclaim aggregation and its two reported alternatives, the five Beta/Gamma/Delta boundary clauses per subclaim, the Delta and Epsilon ladder for SC2, the independence discussion, and the Momentum, Stability and Divergence artifacts. The framework validator was re-run after editing.

**Findings.**

| ID | Severity | Location | Original to corrected | Evidence |
|---|---|---|---|---|
| D1 | Minor | Final score, causal direction and M/S/D; score card divergence block | "Divergence: Contested. No manufactured field consensus or arithmetic gap." replaced by the same verdict carrying its required artifact: the two framings and why no single implied level applies | Framework, Divergence: "Required artifact: state the implied level and the arithmetic." Contested is the one value for which no single implied level exists, so the artifact is the named split. Verdict, level and confidence unchanged |
| D2 | Minor | Consensus and original-source reconciliation | "hazard ratio1.16, confidence interval0.82-1.64" and "immune-marker changes over14days" corrected to spaced forms | Round-2 brief, known upstream defect 4. The ORBEX values were re-verified against the primary abstract before the edit: hazard ratio 1.16, 95% CI 0.82-1.64 |
| D3 | Editorial | REFERENCES item 35 | "DOI: ." corrected to "DOI: none indexed." | Known upstream defect 4 (empty DOI field). PubMed indexes no DOI for PMID 9179425 (Clinical and Experimental Allergy, 1997), so the empty field was correct in substance but rendered as a defect |
| D4 | Minor | Score card `final_score.confidence_rationale` | "density, heterogeneous controls and incomplete access set the confidence" corrected to drop access depth as a determinant and to record the re-test against the High band | Framework, Confidence band: "Confidence reflects evidence density and reproducibility." The reviewer's own read depth is not a property of the evidence. The band was then re-tested against the High text, "extensive independent replication across labs, models, and assay modalities", and holds at Moderate for the reasons given in the rationale. No band change. |

**Rejected findings (checked, no change).**

1. Gamma for SC3 despite two positive randomized human trials. This was the main candidate for a level change and it does not survive. The positive trials supply a defined product to a high-risk population and measure eczema; they do not perturb the registered exposure construct, which is a general early-life microbial deficit across allergic and autoimmune disease. The review assigns that evidence to SC2 at Epsilon and keeps SC3 at Gamma, which is the cap-precedence rule working as written: the perturbation crosses its threshold within the system it was run in, while the universal cap governs the inference to the claimed scope. No change.
2. Aggregation. Primary-subclaim on SC3 is declared before scoring and returns Gamma, and the review reports weakest-link as Beta and scope-matched as Gamma. Scope-matched is the value flagged for this round, so it was checked specifically: SC2's Epsilon is scope-restricted to a defined strain, factor, window and model, so it cannot set a headline whose scope is the full human disease classes. Correct as written.
3. Epsilon rather than Delta for SC2. The context boundary is mapped rather than merely untested: strain-by-strain divergence within one randomization, an adverse sensitisation result, and host-genotype-dependent reversal of direction. Epsilon is the right rung under the failed-generalization rule.
4. Role of mechanism "reinforcing / stabilizing factor", derived through the numbered direction steps to step 5, with the direction explicitly stated as factor- and host-dependent. Defensible.
5. Momentum "Mechanistic only". The artifact names specific work (PMID 31235962, 42517701, 35930838, 38688234) and treats ORBEX as completed rather than pending, which is exactly what the framework asks for. This is the defect flagged for this round and it is not present here.
6. Stability "Stable", with the bounded nature of the search disclosed. Correct where no pending result is named.
7. Timeline years. Each dated milestone matches the publication year of the record it cites.
8. The review's separation of LEAP and EAT as food-antigen tolerance rather than microbial restoration, and its retention of the EAT intention-to-treat null. Checked against both records; correct and material to the verdict.

9. Whether the confidence band should move to High once access depth is removed as a determinant. Re-tested against the framework text: the controlled human evidence is a small set of short trials whose results diverge by strain and endpoint, with several reports sharing one parent randomization and overlapping cohorts; that is the Moderate text, not the High text. The band holds at Moderate. The superseded wording is preserved in the dated audit snapshots in this folder by design.
10. The coordinator-flagged Consensus-splice artifacts do not apply: this case is not one of the 2026-10-09 revised editions, carries no spliced provenance block and no "earlier adversarial approval" clause. Its Consensus reconciliation section is original to the review.
11. The "Best-supported rival" renderer defect reported elsewhere in this round. Checked against the score card: `models_evaluated[0]` here is M2, `is_nominal: false`, `rank_in_tournament: 1`, and the nominal sits at rank 3. The prose names the rival correctly. No change.

**Residual limitations.** Access is six partial-body and 57 bounded abstract or status examinations, so figures attributed to Methods and Results sections that the abstracts do not reproduce - the recruited risk mix in the Welsh trial, the adult age of the mice in the Amish dust experiment, the ineffective short-chain fatty acid mixture and the absence of durable Clostridial engraftment in the bacteriotherapy study, and the intraperitoneal route in the NOD lipopolysaccharide experiment - were checked for internal consistency but could not be confirmed against a complete paper in this pass. The autoimmune clinical branch of the registered claim rests on observational and model evidence only, which the review states. No independent blinded calibration or scientific peer review is claimed by this adversarial pass.

**Approval:** Following adversarial review and the corrections listed above, the revised document is approved. - Claude Opus 5.5 (Anthropic), 2026-10-14.

## REFERENCES

1. Stein MM, Hrusch CL, Gozdz J et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. The New England journal of medicine. 2016. [PMID 27518660](https://pubmed.ncbi.nlm.nih.gov/27518660/). DOI: 10.1056/NEJMoa1508749. Access: full_text_partial. Study: PMID27518660.

2. Ege MJ, Mayer M, Normand AC et al. Exposure to environmental microorganisms and childhood asthma. The New England journal of medicine. 2011. [PMID 21345099](https://pubmed.ncbi.nlm.nih.gov/21345099/). DOI: 10.1056/NEJMoa1007302. Access: abstract_metadata. Study: PMID21345099.

3. Kalliomäki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet (London, England). 2001. [PMID 11297958](https://pubmed.ncbi.nlm.nih.gov/11297958/). DOI: 10.1016/S0140-6736(00)04259-8. Access: abstract_metadata. Study: FINN_LGG.

4. Kalliomäki M, Salminen S, Poussa T et al. Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial. Lancet (London, England). 2003. [PMID 12788576](https://pubmed.ncbi.nlm.nih.gov/12788576/). DOI: 10.1016/S0140-6736(03)13490-3. Access: abstract_metadata. Study: FINN_LGG.

5. Wickens K, Black PN, Stanley TV et al. A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. The Journal of allergy and clinical immunology. 2008. [PMID 18762327](https://pubmed.ncbi.nlm.nih.gov/18762327/). DOI: 10.1016/j.jaci.2008.07.011. Access: abstract_metadata. Study: NZ_HN001_HN019.

6. Wickens K, Black P, Stanley TV et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2012. [PMID 22702506](https://pubmed.ncbi.nlm.nih.gov/22702506/). DOI: 10.1111/j.1365-2222.2012.03975.x. Access: abstract_metadata. Study: NZ_HN001_HN019.

7. Rautava S, Kainonen E, Salminen S et al. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. The Journal of allergy and clinical immunology. 2012. [PMID 23083673](https://pubmed.ncbi.nlm.nih.gov/23083673/). DOI: 10.1016/j.jaci.2012.09.003. Access: abstract_metadata. Study: FINN_MATERNAL_MIX.

8. Abrahamsson TR, Jakobsson T, Böttcher MF et al. Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. The Journal of allergy and clinical immunology. 2007. [PMID 17349686](https://pubmed.ncbi.nlm.nih.gov/17349686/). DOI: 10.1016/j.jaci.2007.01.007. Access: abstract_metadata. Study: PMID17349686.

9. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. The Journal of allergy and clinical immunology. 2007. [PMID 17208600](https://pubmed.ncbi.nlm.nih.gov/17208600/). DOI: 10.1016/j.jaci.2006.08.036. Access: abstract_metadata. Study: PMID17208600.

10. Boyle RJ, Ismail IH, Kivivuori S et al. Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial. Allergy. 2011. [PMID 21121927](https://pubmed.ncbi.nlm.nih.gov/21121927/). DOI: 10.1111/j.1398-9995.2010.02507.x. Access: abstract_metadata. Study: PMID21121927.

11. Allen SJ, Jordan S, Storey M et al. Probiotics in the prevention of eczema: a randomised controlled trial. Archives of disease in childhood. 2014. [PMID 24947281](https://pubmed.ncbi.nlm.nih.gov/24947281/). DOI: 10.1136/archdischild-2013-305799. Access: full_text_partial. Study: WALES_ISRCTN26287422.

12. Davies G, Jordan S, Brooks CJ et al. Long term extension of a randomised controlled trial of probiotics using electronic health records. Scientific reports. 2018. [PMID 29769554](https://pubmed.ncbi.nlm.nih.gov/29769554/). DOI: 10.1038/s41598-018-25954-z. Access: abstract_metadata. Study: WALES_ISRCTN26287422.

13. Cabana MD, McKean M, Caughey AB et al. Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial. Pediatrics. 2017. [PMID 28784701](https://pubmed.ncbi.nlm.nih.gov/28784701/). DOI: 10.1542/peds.2016-3000. Access: abstract_metadata. Study: PMID28784701.

14. Loo EX, Llanora GV, Lu Q et al. Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up. International archives of allergy and immunology. 2014. [PMID 24247661](https://pubmed.ncbi.nlm.nih.gov/24247661/). DOI: 10.1159/000356338. Access: abstract_metadata. Study: PMID24247661.

15. Shipton EV, Foxcroft K, Dekker Nitert M et al. OFFSPRING: A SPRING Follow-Up Study Assessing the Efficacy of Maternal Probiotics and Allergic Disease in the Child. International archives of allergy and immunology. 2024. [PMID 38104554](https://pubmed.ncbi.nlm.nih.gov/38104554/). DOI: 10.1159/000535179. Access: abstract_metadata. Study: PMID38104554.

16. Kallio S, Kukkonen AK, Savilahti E et al. Perinatal probiotic intervention prevented allergic disease in a Caesarean-delivered subgroup at 13-year follow-up. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2019. [PMID 30472801](https://pubmed.ncbi.nlm.nih.gov/30472801/). DOI: 10.1111/cea.13321. Access: abstract_metadata. Study: FINN_MIX_NCT00298337.

17. Puisto R, Gómez-Gallego C, Collado MC et al. The Role of Infant Gut Microbiota Modulation by Perinatal Maternal Probiotic Intervention in Atopic Eczema Risk Reduction. Neonatology. 2025. [PMID 39074448](https://pubmed.ncbi.nlm.nih.gov/39074448/). DOI: 10.1159/000540075. Access: abstract_metadata. Study: FINN_MATERNAL_MIX.

18. Anania C, Matys V, Marra S et al. Effect of Supplementation with a Specific Probiotic (Bifidobacterium bifidum PRL2010) in Pregnancy for the Prevention of Atopic Dermatitis in Children: Preliminary Results of a Randomized Trial. Nutrients. 2025. [PMID 40005000](https://pubmed.ncbi.nlm.nih.gov/40005000/). DOI: 10.3390/nu17040673. Access: abstract_metadata. Study: PMID40005000.

19. Morgan WJ, Mauger DT, Bacharier LB et al. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial. Lancet (London, England). 2026. [PMID 42705251](https://pubmed.ncbi.nlm.nih.gov/42705251/). DOI: 10.1016/S0140-6736(26)01443-1. Access: abstract_metadata. Study: ORBEX_NCT02148796.

20. Rautava S, Kalliomäki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. The Journal of allergy and clinical immunology. 2002. [PMID 11799376](https://pubmed.ncbi.nlm.nih.gov/11799376/). DOI: 10.1067/mai.2002.120273. Access: abstract_metadata. Study: FINN_LGG.

21. Marschan E, Kuitunen M, Kukkonen K et al. Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2008. [PMID 18266878](https://pubmed.ncbi.nlm.nih.gov/18266878/). DOI: 10.1111/j.1365-2222.2008.02942.x. Access: abstract_metadata. Study: FINN_MIX_NCT00298337.

22. P K, M K, K K et al. Interaction of NPSR1 genotypes and probiotics in the manifestation of atopic eczema in early childhood. Allergologia et immunopathologia. 2014. [PMID 24439655](https://pubmed.ncbi.nlm.nih.gov/24439655/). DOI: 10.1016/j.aller.2013.10.001. Access: abstract_metadata. Study: FINN_MIX_NCT00298337.

23. Marlow G, Han DY, Wickens K et al. Differential effects of two probiotics on the risks of eczema and atopy associated with single nucleotide polymorphisms to Toll-like receptors. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2015. [PMID 25779902](https://pubmed.ncbi.nlm.nih.gov/25779902/). DOI: 10.1111/pai.12371. Access: abstract_metadata. Study: NZ_HN001_HN019.

24. Kim JY, Kwon JH, Ahn SH et al. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2010. [PMID 19840300](https://pubmed.ncbi.nlm.nih.gov/19840300/). DOI: 10.1111/j.1399-3038.2009.00958.x. Access: abstract_metadata. Study: PMID19840300.

25. Schmidt RM, Pilmann Laursen R, Bruun S et al. Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2019. [PMID 30790361](https://pubmed.ncbi.nlm.nih.gov/30790361/). DOI: 10.1111/pai.13018. Access: abstract_metadata. Study: PMID30790361.

26. Arrieta MC, Stiemsma LT, Dimitriu PA et al. Early infancy microbial and metabolic alterations affect risk of childhood asthma. Science translational medicine. 2015. [PMID 26424567](https://pubmed.ncbi.nlm.nih.gov/26424567/). DOI: 10.1126/scitranslmed.aab2271. Access: abstract_metadata. Study: PMID26424567.

27. Depner M, Taft DH, Kirjavainen PV et al. Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma. Nature medicine. 2020. [PMID 33139948](https://pubmed.ncbi.nlm.nih.gov/33139948/). DOI: 10.1038/s41591-020-1095-x. Access: abstract_metadata. Study: PMID33139948.

28. Pagani G, Loss G, Pechlivanis S et al. Gram-Positive Bacteria and the Inverse Association between Farm Exposure and Childhood Asthma. NEJM evidence. 2026. [PMID 42517701](https://pubmed.ncbi.nlm.nih.gov/42517701/). DOI: 10.1056/EVIDoa2500271. Access: abstract_metadata. Study: PMID42517701.

29. Lluis A, Depner M, Gaugler B et al. Increased regulatory T-cell numbers are associated with farm milk exposure and lower atopic sensitization and asthma in childhood. The Journal of allergy and clinical immunology. 2014. [PMID 23993223](https://pubmed.ncbi.nlm.nih.gov/23993223/). DOI: 10.1016/j.jaci.2013.06.034. Access: abstract_metadata. Study: PMID23993223.

30. Lundell AC, Hesselmar B, Nordström I et al. Higher B-cell activating factor levels at birth are positively associated with maternal dairy farm exposure and negatively related to allergy development. The Journal of allergy and clinical immunology. 2015. [PMID 25936566](https://pubmed.ncbi.nlm.nih.gov/25936566/). DOI: 10.1016/j.jaci.2015.03.022. Access: abstract_metadata. Study: PMID25936566.

31. Kääriö H, Nieminen JK, Karvonen AM et al. Circulating Dendritic Cells, Farm Exposure and Asthma at Early Age. Scandinavian journal of immunology. 2016. [PMID 26368653](https://pubmed.ncbi.nlm.nih.gov/26368653/). DOI: 10.1111/sji.12389. Access: abstract_metadata. Study: PMID26368653.

32. Lluis A, Ballenberger N, Illi S et al. Regulation of TH17 markers early in life through maternal farm exposure. The Journal of allergy and clinical immunology. 2014. [PMID 24275363](https://pubmed.ncbi.nlm.nih.gov/24275363/). DOI: 10.1016/j.jaci.2013.09.030. Access: abstract_metadata. Study: PMID24275363.

33. Hasegawa K, Linnemann RW, Mansbach JM et al. Household siblings and nasal and fecal microbiota in infants. Pediatrics international : official journal of the Japan Pediatric Society. 2017. [PMID 27638139](https://pubmed.ncbi.nlm.nih.gov/27638139/). DOI: 10.1111/ped.13168. Access: abstract_metadata. Study: PMID27638139.

34. Swaney MH, Steidl OR, Tackett A et al. Farm exposure is associated with human breast milk immune profile and microbiome. bioRxiv : the preprint server for biology. 2024. [PMID 39464075](https://pubmed.ncbi.nlm.nih.gov/39464075/). DOI: 10.1101/2024.10.14.618271. Access: abstract_metadata. Study: PMID39464075.

35. Räsänen M, Laitinen T, Kaprio J et al. Hay fever, asthma and number of older siblings--a twin study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 1997. [PMID 9179425](https://pubmed.ncbi.nlm.nih.gov/9179425/). DOI: none indexed. Access: abstract_metadata. Study: PMID9179425.

36. Ball TM, Castro-Rodriguez JA, Griffith KA et al. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. The New England journal of medicine. 2000. [PMID 10954761](https://pubmed.ncbi.nlm.nih.gov/10954761/). DOI: 10.1056/NEJM200008243430803. Access: abstract_metadata. Study: PMID10954761.

37. Rennie DC, Karunanayake CP, Chen Y et al. Early farm residency and prevalence of asthma and hay fever in adults. The Journal of asthma : official journal of the Association for the Care of Asthma. 2016. [PMID 26377166](https://pubmed.ncbi.nlm.nih.gov/26377166/). DOI: 10.3109/02770903.2015.1058394. Access: abstract_metadata. Study: PMID26377166.

38. Birzele LT, Depner M, Ege MJ et al. Environmental and mucosal microbiota and their role in childhood asthma. Allergy. 2017. [PMID 27503830](https://pubmed.ncbi.nlm.nih.gov/27503830/). DOI: 10.1111/all.13002. Access: abstract_metadata. Study: PMID27503830.

39. Vatanen T, Kostic AD, d'Hennezel E et al. Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans. Cell. 2016. [PMID 27133167](https://pubmed.ncbi.nlm.nih.gov/27133167/). DOI: 10.1016/j.cell.2016.04.007. Access: full_text_partial. Study: PMID27133167.

40. Kostic AD, Gevers D, Siljander H et al. The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes. Cell host & microbe. 2015. [PMID 25662751](https://pubmed.ncbi.nlm.nih.gov/25662751/). DOI: 10.1016/j.chom.2015.01.001. Access: abstract_metadata. Study: PMID25662751.

41. Markle JG, Frank DN, Mortin-Toth S et al. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science (New York, N.Y.). 2013. [PMID 23328391](https://pubmed.ncbi.nlm.nih.gov/23328391/). DOI: 10.1126/science.1233521. Access: abstract_metadata. Study: PMID23328391.

42. Wen L, Ley RE, Volchkov PY et al. Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature. 2008. [PMID 18806780](https://pubmed.ncbi.nlm.nih.gov/18806780/). DOI: 10.1038/nature07336. Access: abstract_metadata. Study: PMID18806780.

43. Olszak T, An D, Zeissig S et al. Microbial exposure during early life has persistent effects on natural killer T cell function. Science (New York, N.Y.). 2012. [PMID 22442383](https://pubmed.ncbi.nlm.nih.gov/22442383/). DOI: 10.1126/science.1219328. Access: full_text_partial. Study: PMID22442383.

44. Atarashi K, Tanoue T, Shima T et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science (New York, N.Y.). 2011. [PMID 21205640](https://pubmed.ncbi.nlm.nih.gov/21205640/). DOI: 10.1126/science.1198469. Access: abstract_metadata. Study: PMID21205640.

45. Atarashi K, Tanoue T, Oshima K et al. Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature. 2013. [PMID 23842501](https://pubmed.ncbi.nlm.nih.gov/23842501/). DOI: 10.1038/nature12331. Access: abstract_metadata. Study: PMID23842501.

46. Stefka AT, Feehley T, Tripathi P et al. Commensal bacteria protect against food allergen sensitization. Proceedings of the National Academy of Sciences of the United States of America. 2014. [PMID 25157157](https://pubmed.ncbi.nlm.nih.gov/25157157/). DOI: 10.1073/pnas.1412008111. Access: abstract_metadata. Study: PMID25157157.

47. Schuijs MJ, Willart MA, Vergote K et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science (New York, N.Y.). 2015. [PMID 26339029](https://pubmed.ncbi.nlm.nih.gov/26339029/). DOI: 10.1126/science.aac6623. Access: abstract_metadata. Study: PMID26339029.

48. Abdel-Gadir A, Stephen-Victor E, Gerber GK et al. Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy. Nature medicine. 2019. [PMID 31235962](https://pubmed.ncbi.nlm.nih.gov/31235962/). DOI: 10.1038/s41591-019-0461-z. Access: full_text_partial. Study: PMID31235962.

49. Mustonen N, Siljander H, Peet A et al. Early childhood infections precede development of beta-cell autoimmunity and type 1 diabetes in children with HLA-conferred disease risk. Pediatric diabetes. 2018. [PMID 28597957](https://pubmed.ncbi.nlm.nih.gov/28597957/). DOI: 10.1111/pedi.12547. Access: abstract_metadata. Study: PMID28597957.

50. Wernroth ML, Fall K, Svennblad B et al. Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis. Diabetes care. 2020. [PMID 32132008](https://pubmed.ncbi.nlm.nih.gov/32132008/). DOI: 10.2337/dc19-1162. Access: abstract_metadata. Study: PMID32132008.

51. Lönnrot M, Lynch KF, Rewers M et al. Gastrointestinal Infections Modulate the Risk for Insulin Autoantibodies as the First-Appearing Autoantibody in the TEDDY Study. Diabetes care. 2023. [PMID 37607456](https://pubmed.ncbi.nlm.nih.gov/37607456/). DOI: 10.2337/dc23-0518. Access: abstract_metadata. Study: TEDDY.

52. Lindfors K, Lin J, Lee HS et al. Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study. Gut. 2020. [PMID 31744911](https://pubmed.ncbi.nlm.nih.gov/31744911/). DOI: 10.1136/gutjnl-2019-319809. Access: abstract_metadata. Study: TEDDY.

53. Russell SL, Gold MJ, Hartmann M et al. Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma. EMBO reports. 2012. [PMID 22422004](https://pubmed.ncbi.nlm.nih.gov/22422004/). DOI: 10.1038/embor.2012.32. Access: abstract_metadata. Study: PMID22422004.

54. Hadebe S, Kirstein F, Fierens K et al. Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma. PloS one. 2015. [PMID 26261989](https://pubmed.ncbi.nlm.nih.gov/26261989/). DOI: 10.1371/journal.pone.0134219. Access: abstract_metadata. Study: PMID26261989.

55. Huang Z, Wang J, Xu X et al. Antibody neutralization of microbiota-derived circulating peptidoglycan dampens inflammation and ameliorates autoimmunity. Nature microbiology. 2019. [PMID 30833732](https://pubmed.ncbi.nlm.nih.gov/30833732/). DOI: 10.1038/s41564-019-0381-1. Access: abstract_metadata. Study: PMID30833732.

56. Horai R, Zárate-Bladés CR, Dillenburg-Pilla P et al. Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site. Immunity. 2015. [PMID 26287682](https://pubmed.ncbi.nlm.nih.gov/26287682/). DOI: 10.1016/j.immuni.2015.07.014. Access: abstract_metadata. Study: PMID26287682.

57. Montgomery TL, Künstner A, Kennedy JJ et al. Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity. Proceedings of the National Academy of Sciences of the United States of America. 2020. [PMID 33077601](https://pubmed.ncbi.nlm.nih.gov/33077601/). DOI: 10.1073/pnas.2002817117. Access: abstract_metadata. Study: PMID33077601.

58. Du Toit G, Roberts G, Sayre PH et al. Randomized trial of peanut consumption in infants at risk for peanut allergy. The New England journal of medicine. 2015. [PMID 25705822](https://pubmed.ncbi.nlm.nih.gov/25705822/). DOI: 10.1056/NEJMoa1414850. Access: full_text_partial. Study: LEAP_PARENT.

59. Perkin MR, Logan K, Tseng A et al. Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants. The New England journal of medicine. 2016. [PMID 26943128](https://pubmed.ncbi.nlm.nih.gov/26943128/). DOI: 10.1056/NEJMoa1514210. Access: abstract_metadata. Study: PMID26943128.

60. Du Toit G, Sayre PH, Roberts G et al. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. The New England journal of medicine. 2016. [PMID 26942922](https://pubmed.ncbi.nlm.nih.gov/26942922/). DOI: 10.1056/NEJMoa1514209. Access: abstract_metadata. Study: LEAP_PARENT.

61. Roslund MI, Puhakka R, Grönroos M et al. Biodiversity intervention enhances immune regulation and health-associated commensal microbiota among daycare children. Science advances. 2020. [PMID 33055153](https://pubmed.ncbi.nlm.nih.gov/33055153/). DOI: 10.1126/sciadv.aba2578. Access: abstract_metadata. Study: PMID33055153.

62. Roslund MI, Parajuli A, Hui N et al. A Placebo-controlled double-blinded test of the biodiversity hypothesis of immune-mediated diseases: Environmental microbial diversity elicits changes in cytokines and increase in T regulatory cells in young children. Ecotoxicology and environmental safety. 2022. [PMID 35930838](https://pubmed.ncbi.nlm.nih.gov/35930838/). DOI: 10.1016/j.ecoenv.2022.113900. Access: abstract_metadata. Study: PMID35930838.

63. Saarenpää M, Roslund MI, Nurminen N et al. Urban indoor gardening enhances immune regulation and diversifies skin microbiota - A placebo-controlled double-blinded intervention study. Environment international. 2024. [PMID 38688234](https://pubmed.ncbi.nlm.nih.gov/38688234/). DOI: 10.1016/j.envint.2024.108705. Access: abstract_metadata. Study: PMID38688234.

## Source-specific evidence cards

### [1] Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children.

**Shows:** Amish/Hutterite asthma and innate-immune differences accompany different dust exposure; Amish dust protects adult mice via MyD88/TRIF.

**Does not show:** Human comparison is nonrandomized; adult dust instillation is not a neonatal deprivation experiment.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:METHODS:paragraph1, 0:METHODS:paragraph6, 1:RESULTS:paragraph6. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [2] Exposure to environmental microorganisms and childhood asthma.

**Shows:** Farm microbial diversity associates inversely with asthma in two population studies.

**Does not show:** Farm setting has multiple correlated exposures; measured diversity mediation is not selective causal manipulation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [3] Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial.

**Shows:** Perinatal LGG reduces primary eczema incidence in a high-risk randomized trial.

**Does not show:** Specific strain/regimen/phenotype; no proof of general asthma or autoimmune prevention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [4] Probiotics and prevention of atopic disease: 4-year follow-up of a randomised placebo-controlled trial.

**Shows:** Finnish LGG follow-up retains eczema benefit but not skin-test reactivity difference.

**Does not show:** Same parent trial with attrition; not independent replication or broad atopy prevention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [5] A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial.

**Shows:** HN001 reduces eczema, while HN019 and sensitization comparisons are null.

**Does not show:** Strain and endpoint boundaries; probiotic exposure is not interchangeable with environmental diversity.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [6] A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years.

**Shows:** HN001 follow-up retains eczema/rhinoconjunctivitis benefit; HN019 and other endpoints remain null or nonsignificant.

**Does not show:** Same randomization as the two-strain study; selected secondary outcomes do not show uniform protection.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [7] Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant.

**Shows:** Maternal probiotic mixtures reduce eczema in infants of allergic mothers.

**Does not show:** No sensitization benefit; incomplete follow-up and selected maternal eligibility limit generalization.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [8] Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial.

**Shows:** L. reuteri trial is null for cumulative eczema but reduces IgE-associated eczema in a subset/time window.

**Does not show:** Primary and secondary findings differ; wheeze is not improved.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [9] Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial.

**Shows:** Early L. acidophilus increases colonization without eczema prevention and with increased sensitization.

**Does not show:** Specific regimen; does not prove all microbial exposure harmful, but contradicts blanket benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [10] Lactobacillus GG treatment during pregnancy for the prevention of eczema: a randomized controlled trial.

**Shows:** Prenatal-only LGG does not prevent eczema or change cord immune markers.

**Does not show:** Timing/regimen boundary; postnatal benefit cannot be assumed from this null.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [11] Probiotics in the prevention of eczema: a randomised controlled trial.

**Shows:** Registered multispecies trial is null for primary diagnosed eczema, with selected positive secondary sensitization/atopic-eczema findings.

**Does not show:** Original Methods preserve broad recruited risk mix and endpoint hierarchy; secondary benefit is not primary success.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Methods:paragraph2, 1:Methods:paragraph9. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [12] Long term extension of a randomised controlled trial of probiotics using electronic health records.

**Shows:** Five-year electronic follow-up of the same trial finds no asthma/eczema protection.

**Does not show:** Shared parent trial, retention and routine-record ascertainment; not independent randomization.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [13] Early Probiotic Supplementation for Eczema and Asthma Prevention: A Randomized Controlled Trial.

**Shows:** Infant LGG/inulin trial shows no significant eczema or asthma prevention.

**Does not show:** CI permits some effects; null cannot be discarded because another LGG regimen worked.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [14] Supplementation with probiotics in the first 6 months of life did not protect against eczema and allergy in at-risk Asian infants: a 5-year follow-up.

**Shows:** PROMPT follow-up finds no allergy/asthma/eczema benefit at five years.

**Does not show:** Same parent intervention and selected at-risk Asian cohort, with follow-up attrition.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [15] OFFSPRING: A SPRING Follow-Up Study Assessing the Efficacy of Maternal Probiotics and Allergic Disease in the Child.

**Shows:** SPRING respondent follow-up finds no allergic-disease advantage after maternal probiotics.

**Does not show:** Small responding subset and questionnaire outcomes limit precision and independence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [16] Perinatal probiotic intervention prevented allergic disease in a Caesarean-delivered subgroup at 13-year follow-up.

**Shows:** Whole-cohort long-term allergy comparison is null with higher inhalant sensitization; favorable cesarean finding is post hoc.

**Does not show:** Baseline delivery mode is measurable, but subgroup choice after results does not prospectively confirm it; substantial attrition.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [17] The Role of Infant Gut Microbiota Modulation by Perinatal Maternal Probiotic Intervention in Atopic Eczema Risk Reduction.

**Shows:** Subset analysis does not find diversity/composition mediation of a prior eczema-prevention benefit.

**Does not show:** Same maternal-mixture trial and selected full-term vaginal/breastfed subset; microbiome modulation is not established as mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [18] Effect of Supplementation with a Specific Probiotic (Bifidobacterium bifidum PRL2010) in Pregnancy for the Prevention of Atopic Dermatitis in Children: Preliminary Results of a Randomized Trial.

**Shows:** Small PRL2010 trial has no significant dermatitis-incidence difference, with favorable severity-course signals.

**Does not show:** Preliminary and subgroup/secondary results; no established prevention benefit.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [19] Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial.

**Shows:** ORBEX randomizes 822 children; OM-85 does not improve primary time to first wheezing lower-respiratory illness in the off-drug observation period.

**Does not show:** Wheezing endpoint and age/lysate regimen are defined; clinical null does not rule out every exposure, and target engagement was not verified here.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [20] Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant.

**Shows:** Maternal LGG study relates changed milk TGF-beta2 to lower infant eczema.

**Does not show:** Related Finnish LGG program/subset; immune-marker association is not proved mediation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [21] Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation.

**Shows:** Probiotic exposure alters infant immune markers, with higher CRP associated with lower later eczema risk.

**Does not show:** Secondary immune analyses in a parent trial; biomarkers and association do not prove the clinical mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [22] Interaction of NPSR1 genotypes and probiotics in the manifestation of atopic eczema in early childhood.

**Shows:** NPSR1 analysis in a probiotic trial finds suggestive eczema associations but no general asthma/sensitization association.

**Does not show:** Exploratory genotype analyses and shared trial recruitment do not validate prospective protective subtypes.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [23] Differential effects of two probiotics on the risks of eczema and atopy associated with single nucleotide polymorphisms to Toll-like receptors.

**Shows:** TLR variants interact differently with HN001 and HN019 in a selected trial subset.

**Does not show:** Many variant/outcome comparisons, European-ancestry selection and parent-trial overlap limit causal independence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [24] Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial.

**Shows:** Probiotic mixture reduces eczema in a small completed high-risk infant cohort.

**Does not show:** Marked attrition and no sensitization/total-IgE difference; no systemic autoimmune endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [25] Probiotics in late infancy reduce the incidence of eczema: A randomized controlled trial.

**Shows:** Late-infant probiotic mixture reduces eczema but not asthma, sensitization or other allergy endpoints.

**Does not show:** Short follow-up and a specific daycare-entry regimen do not establish a universal neonatal window.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [26] Early infancy microbial and metabolic alterations affect risk of childhood asthma.

**Shows:** CHILD early taxa/metabolite deficits precede asthma risk; defined bacteria improve airway inflammation in recipient progeny.

**Does not show:** Human risk association and germ-free transfer differ in scope; early wheeze/atopy is not every later clinical asthma phenotype.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2, SC3.

### [27] Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma.

**Shows:** PASTURE microbiome maturation and butyrate measures relate to farm protection and later asthma.

**Does not show:** Statistical mediation shares exposure/confounding and microbiome model assumptions.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [28] Gram-Positive Bacteria and the Inverse Association between Farm Exposure and Childhood Asthma.

**Shows:** Replicated farm-dust genera/metabolite and receptor-interaction analyses explain much of an inverse asthma association.

**Does not show:** Mediation, inferred microbial functions and gene-environment interaction do not replace selective human exposure randomization.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [29] Increased regulatory T-cell numbers are associated with farm milk exposure and lower atopic sensitization and asthma in childhood.

**Shows:** Farm milk exposure associates with Treg measures and lower asthma/sensitization.

**Does not show:** Diet, milk components and farming covary; immune cells are not a verified causal mediator.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [30] Higher B-cell activating factor levels at birth are positively associated with maternal dairy farm exposure and negatively related to allergy development.

**Shows:** Maternal farm exposure and neonatal BAFF/B-cell maturation associate with later allergy measures.

**Does not show:** Observational FARMFLORA cohort, small immune-marker comparisons and sex differences limit causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [31] Circulating Dendritic Cells, Farm Exposure and Asthma at Early Age.

**Shows:** PASTURE farm exposure and dendritic-cell properties associate with childhood asthma.

**Does not show:** Selected subset, in-vitro stimulation and shared cohort do not give independent disease perturbation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [32] Regulation of TH17 markers early in life through maternal farm exposure.

**Shows:** Maternal farming alters some TH17/Treg relationships but not baseline TH17 marker expression.

**Does not show:** Prenatal genetics/exposure correlations and marker endpoints do not prove prevention.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [33] Household siblings and nasal and fecal microbiota in infants.

**Shows:** Siblings associate with infant nasal/fecal community profiles.

**Does not show:** Cross-sectional microbial composition has no direct later disease intervention endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

### [34] Farm exposure is associated with human breast milk immune profile and microbiome.

**Shows:** Maternal farm groups differ in milk microbial and immune-protein profiles.

**Does not show:** Milk profiles are not a trial of later clinical allergy or autoimmune incidence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

### [35] Hay fever, asthma and number of older siblings--a twin study.

**Shows:** More older siblings relates to lower hay fever but not asthma in a twin-family survey.

**Does not show:** Family size is an exposure proxy with disease-specific nulls and shared familial causes.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [36] Siblings, day-care attendance, and the risk of asthma and wheezing during childhood.

**Shows:** Sibling/daycare contact associates with more early wheeze and less later wheeze/asthma.

**Does not show:** Age reversal and nonrandomized social exposure prevent a simple protective-microbe interpretation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [37] Early farm residency and prevalence of asthma and hay fever in adults.

**Shows:** Early farm residence is protective in some sex-specific adult outcomes; current-only exposure can relate to higher asthma risk.

**Does not show:** Recall, occupation and sex-dependent confounding; not prospective selective exposure manipulation.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [38] Environmental and mucosal microbiota and their role in childhood asthma.

**Shows:** Farm-related dust diversity has a stronger inverse asthma association than nasal diversity.

**Does not show:** Association and several nonsignificant richness/nasal comparisons; no causal environmental metabolite test.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [39] Variation in Microbiome LPS Immunogenicity Contributes to Autoimmunity in Humans.

**Shows:** LPS structural activity differs by microbial source; E. coli but not B. dorei LPS protects NOD mice.

**Does not show:** Human infant data are observational; mouse LPS is intraperitoneal, not natural mucosal colonization; correction retained.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Results:paragraph15. No complete-paper or supplement audit claimed. ErratumIn: PMID27259157. Subclaims: SC1, SC2, SC3.

### [40] The dynamics of the human infant gut microbiome in development and in progression toward type 1 diabetes.

**Shows:** Infant T1D progressors show diversity loss between seroconversion and diagnosis.

**Does not show:** Temporal changes after autoimmunity begins cannot prove microbial deficiency initiated it.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [41] Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity.

**Shows:** Male-to-female microbiota transfer alters hormones and protects NOD recipients through androgen signaling.

**Does not show:** Genotype/sex and forced-transfer context restrict endogenous human inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [42] Innate immunity and intestinal microbiota in the development of Type 1 diabetes.

**Shows:** Commensals and defined colonization modify diabetes in MyD88-deficient NOD mice.

**Does not show:** Germ-free/genotype context and broad innate signaling are not a human population necessity proof.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [43] Microbial exposure during early life has persistent effects on natural killer T cell function.

**Shows:** Neonatal but not adult colonization prevents excess iNKT and induced lung/colitis pathology.

**Does not show:** Germ-free developmental deprivation and induced models require separate human adjudication.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 1:Main text:paragraph5, 1:Main text:paragraph8. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [44] Induction of colonic regulatory T cells by indigenous Clostridium species.

**Shows:** Defined Clostridia increase colonic Treg function and resistance to induced disease.

**Does not show:** Specific community/model effects do not imply every microbe or all disease classes are protective.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [45] Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota.

**Shows:** A selected 17-strain human-derived consortium improves Treg function and induced mouse pathology.

**Does not show:** Human origin of strains is not a human clinical trial; selected consortium and recipient physiology set scope.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [46] Commensal bacteria protect against food allergen sensitization.

**Shows:** Defined Clostridia colonization protects allergen sensitization through barrier/innate-cell effects.

**Does not show:** Antibiotic and gnotobiotic preparations restrict ordinary human incidence inference.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [47] Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells.

**Shows:** Low-dose dust/endotoxin protects experimental asthma, requiring epithelial A20.

**Does not show:** Exposure identity, dose and barrier pathway are specific; human A20 association is not intervention evidence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [48] Microbiota therapy acts via a regulatory T cell MyD88/RORγt pathway to suppress food allergy.

**Shows:** Defined live consortia suppress model food allergy through Treg MyD88/RORgamma-t necessity.

**Does not show:** SCFA mixture fails and durable Clostridial engraftment is not established; genetic allergy model and correction limit broad human transfer.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Results:paragraph16, 0:Results:paragraph17, 0:Results:paragraph20, 0:Results:paragraph21. No complete-paper or supplement audit claimed. ErratumIn: PMID31420602. Subclaims: SC2.

### [49] Early childhood infections precede development of beta-cell autoimmunity and type 1 diabetes in children with HLA-conferred disease risk.

**Shows:** More and earlier infections precede islet autoimmunity/progression in genetically susceptible children.

**Does not show:** Few clinical progressors and immune susceptibility/reverse-causality alternatives; infection is not equivalent to benign commensal exposure.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [50] Early Childhood Antibiotic Treatment for Otitis Media and Other Respiratory Tract Infections Is Associated With Risk of Type 1 Diabetes: A Nationwide Register-Based Study With Sibling Analysis.

**Shows:** Infant antibiotic prescription associates with later T1D, with generally compatible but often nonsignificant sibling results.

**Does not show:** Indication, infection and direct drug effects remain; no selective commensal-deprivation causal test.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [51] Gastrointestinal Infections Modulate the Risk for Insulin Autoantibodies as the First-Appearing Autoantibody in the TEDDY Study.

**Shows:** TEDDY gastrointestinal infection associations with autoantibodies change direction by age and timing.

**Does not show:** Autoantibody endpoints and exposure-specific effects do not show universal clinical autoimmune protection.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [52] Metagenomics of the faecal virome indicate a cumulative effect of enterovirus and gluten amount on the risk of coeliac disease autoimmunity in genetically at risk children: the TEDDY study.

**Shows:** Enterovirus exposure and gluten interaction associate with increased celiac autoimmunity.

**Does not show:** Genetic-risk nested cohort; combines viral and dietary factors rather than a generalized microbial-deficit mechanism.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

### [53] Early life antibiotic-driven changes in microbiota enhance susceptibility to allergic asthma.

**Shows:** Neonatal vancomycin but not streptomycin increases experimental asthma; adult treatment is null.

**Does not show:** Antibiotic and developmental pleiotropy remain, with explicit drug and age boundaries.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [54] Microbial Ligand Costimulation Drives Neutrophilic Steroid-Refractory Asthma.

**Shows:** Combined LPS/beta-glucan promotes steroid-refractory inflammatory asthma through Dectin-1/TLR4.

**Does not show:** Different dose/route/context; genuine contrary direction to blanket microbial protection, with linked correction retained.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. ErratumIn: PMID26348039. Subclaims: SC2.

### [55] Antibody neutralization of microbiota-derived circulating peptidoglycan dampens inflammation and ameliorates autoimmunity.

**Shows:** Neutralizing circulating microbial peptidoglycan reduces autoimmune arthritis/EAE with NOD2 dependence.

**Does not show:** Adult systemic microbial-factor effects are not early-life deprivation, but show harmful commensal signaling can be causal.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [56] Microbiota-Dependent Activation of an Autoreactive T Cell Receptor Provokes Autoimmunity in an Immunologically Privileged Site.

**Shows:** Commensal-dependent autoreactive TCR activation triggers spontaneous uveitis in a model.

**Does not show:** Genetically restricted model; does not establish the human attributable fraction.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [57] Interactions between host genetics and gut microbiota determine susceptibility to CNS autoimmunity.

**Shows:** Microbiome transfer and defined L. reuteri can worsen EAE in selected genotypes.

**Does not show:** Host genetics reverses the effect of a nominal probiotic; not a universal species label or human intervention result.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

### [58] Randomized trial of peanut consumption in infants at risk for peanut allergy.

**Shows:** Early peanut feeding prevents oral-challenge-confirmed peanut allergy in predefined at-risk cohorts.

**Does not show:** Dietary antigen exposure, not microbial restoration; linked correction details unexamined; cannot be credited as hygiene-mechanism proof.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. Selected body sections: 0:Methods:paragraph1, 0:Methods:paragraph4, 1:Results:paragraph1, 1:Results:paragraph2. No complete-paper or supplement audit claimed. ErratumIn: PMID27464222. Subclaims: SC3.

### [59] Randomized Trial of Introduction of Allergenic Foods in Breast-Fed Infants.

**Shows:** EAT has a null intention-to-treat food-allergy primary outcome and favorable adherent/subtype analyses.

**Does not show:** Dietary antigen intervention and per-protocol selection do not prove microbial-deprivation causality.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [60] Effect of Avoidance on Peanut Allergy after Early Peanut Consumption.

**Shows:** LEAP-On retains food-allergen tolerance after avoidance in the earlier consumption group.

**Does not show:** Same parent cohort; not independent microbial prevention evidence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

### [61] Biodiversity intervention enhances immune regulation and health-associated commensal microbiota among daycare children.

**Shows:** Short daycare biodiversity intervention changes skin/gut communities and immune markers.

**Does not show:** Short-term marker endpoints do not demonstrate reduced allergic or autoimmune disease incidence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [62] A Placebo-controlled double-blinded test of the biodiversity hypothesis of immune-mediated diseases: Environmental microbial diversity elicits changes in cytokines and increase in T regulatory cells in young children.

**Shows:** Blinded sandbox comparison with 13 children per group changes cytokine/community measures.

**Does not show:** Age 3-5, very small groups and biomarker outcomes; no verified clinical prevention endpoint.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

### [63] Urban indoor gardening enhances immune regulation and diversifies skin microbiota - A placebo-controlled double-blinded intervention study.

**Shows:** Blinded indoor gardening changes skin microbial diversity and IL-10.

**Does not show:** Adult volunteer intervention and short immune-marker outcomes are not early-life disease-incidence evidence.

**Access/status:** Bounded original primary abstract Results/Findings/conclusion passages and linked-status metadata examined; no complete-abstract audit asserted. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.